Bellevue Life Sciences AcquiBLACU
13F holders, Q4 2024 (December 31)3holders
0new positions
0sold out
$11.82avg. 13F price*
At the end of Q4 2024, 3 institutions reported holding Bellevue Life Sciences Acqui (BLACU) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were Clear Street LLC ($56K), UBS Group AG ($6K) and Tower Research Capital LLC (TRC) ($116).
- Company
- Bellevue Life Sciences Acqui
- CUSIP
- 079174207
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 500 shares bought, net +500 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Clear Street LLC | 0.00% | Add +12.0% | 4,679 | $56K |
| UBS Group AG | 0.00% | No change | 500 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | No change | 10 | $116 |
"% of holder's portfolio" is BLACU's weight in each manager's 13F, not the share of Bellevue Life Sciences Acqui the manager owns.